Akebia Therapeutics (AKBA) Stock Forecast & Price Target

Akebia Therapeutics is well positioned because Vafseo launched in January 2025 in DD-CKD with nearly 100% contract coverage, no U.S. oral or non-ESA competitor in the category, and access to a >540k-patient TAM that includes 80k home-dialysis patients and 150k high-ESA users. Its positive thesis is reinforced by VOICE, which met predefined stopping criteria with a win odds of 1.16, showed non-inferiority and superiority versus ESAs, and reduced hospitalizations, supporting broader dialysis adoption before TDAPA ends in 2027. Beyond Vafseo, AKB-097 and praliciguat add long-duration, differentiated opportunities in large kidney-disease markets where safer, mechanism-specific therapies can command meaningful value.

Akebia Therapeutics is challenged by the inherent volatility of a development-stage biopharmaceutical business, where clinical readouts, regulatory decisions, and pricing-sensitive commercialization can quickly undermine value. Its outlook is further pressured by execution risk around peak revenue assumptions for its commercial products, while ongoing program development and commercialization still require sustained success across a narrow portfolio. The company also faces meaningful financing risk, as failure to secure capital resources to fund operations could limit progress even though its valuation work relies on discounted cash flow and 2036 EPS assumptions that remain highly sensitive to those inputs.